Ivacaftor

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1323 publications

Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a PBPK modeling approach.

Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a PBPK modeling approach.

Journal: Expert opinion on drug metabolism & toxicology

Published: June 13, 2026

Targeting von Willebrand factor selectively under inflammatory conditions.

Targeting von Willebrand factor selectively under inflammatory conditions.

Journal: bioRxiv : the preprint server for biology

Published: May 13, 2026

CFTR modulator monotherapy for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

CFTR modulator monotherapy for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

Journal: The Cochrane database of systematic reviews

Published: May 07, 2026

Functional Rescue of CFTR-Dependent Transport in a Pancreatic Ductal Epithelial Cell Model: The Impact of Pharmacological Modulation and Inflammation.

Functional Rescue of CFTR-Dependent Transport in a Pancreatic Ductal Epithelial Cell Model: The Impact of Pharmacological Modulation and Inflammation.

Journal: International journal of molecular sciences

Published: April 28, 2026

Lighting up the linear ubiquitin code: a bioluminescent sensor for M1-specific deubiquitinase activity and drug discovery.

Lighting up the linear ubiquitin code: a bioluminescent sensor for M1-specific deubiquitinase activity and drug discovery.

Journal: Chemical communications (Cambridge, England)

Published: April 20, 2026

ETI corrector therapy suppresses mitochondrial respiration independently of CFTR mutational status.

ETI corrector therapy suppresses mitochondrial respiration independently of CFTR mutational status.

Journal: Biochemical and biophysical research communications

Published: April 10, 2026

The role of real-world data and real-world evidence in advancing regulatory science and targeted therapeutics: a narrative review from the United States perspective.

The role of real-world data and real-world evidence in advancing regulatory science and targeted therapeutics: a narrative review from the United States perspective.

Journal: Personalized medicine

Published: April 04, 2026

Addressing the Release and Permeation Challenges of High-Tg Drugs in Amorphous Solid Dispersions.

Addressing the Release and Permeation Challenges of High-Tg Drugs in Amorphous Solid Dispersions.

Journal: Molecular pharmaceutics

Published: March 25, 2026

Comment on 'Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators'.

Comment on 'Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators'.

Journal: Acta paediatrica (Oslo, Norway : 1992)

Published: March 13, 2026

Evolution of thoracic computed tomography after therapy with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis

Evolution of thoracic computed tomography after therapy with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis

Journal: Revue medicale de Liege

Published: March 12, 2026

Keeping up with CFTR modulator eligibility.

Keeping up with CFTR modulator eligibility.

Journal: Paediatric respiratory reviews

Published: March 10, 2026

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence.

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence.

Journal: Journal of clinical medicine

Published: February 19, 2026

Showing 1-12 of 1,323

Last Updated: 06/30/2026